ATA THYROIDRisk Stratification for Differentiated Cancer
Note: ATA risk is distinct from AJCC staging. ATA risk predicts the likelihood of recurrence, while AJCC predicts the likelihood of mortality.
Risk Profile
Recurrence Outlook
Low risk of structural recurrence (< 5%). Routine follow-up with thyroglobulin monitoring is standard.
Verified
Last Review: 2026
| Category | Typical Findings |
|---|---|
| Low Risk | Intrathyroidal tumor, < 5 nodes (all < 2mm), no vascular invasion. |
| Intermediate Risk | Microscopic ETE, vascular invasion, or > 5 nodes (all < 3cm). |
| High Risk | Gross ETE, incomplete resection, distant metastases, or bulky nodes (≥ 3cm). |
| Category | Risk of Structural Recurrence |
|---|---|
| Low Risk | < 5% |
| Intermediate Risk | 10 - 20% |
| High Risk | 30 - 55% |
Haugen BR et al. • Thyroid. 2016;26(1):1-133
Last Comprehensive Review: 2026
Clinical Context
We think this has broad domain relevance to ATA Thyroid Recurrence Risk.
Clinical Context
We think this has broad domain relevance to ATA Thyroid Recurrence Risk.
Clinical Context
We think this might be relevant to the clinical guidance for ATA Thyroid Recurrence Risk.